Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Rituximab
DATE: 26/04/2020
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
